OBJECTIVE: Ovarian carcinosarcomas (OCS) are rare tumors composed of both malignant epithelial and mesenchymal elements. We compared the natural history and outcomes of OCS to serous carcinoma of the ovary. METHODS: Patients with OCS and serous carcinomas registered in the Surveillance, Epidemiology, and End Results (SEER) database between 1988 and 2007 were analyzed. Demographic and clinical characteristics were compared using chi square tests while survival was analyzed using Cox proportional hazards models and the Kaplan-Meier method. RESULTS: A total of 27,737 women, including 1763 (6.4%) with OCS and 25,974 (93.6%) with serous carcinomas, were identified. Patients with carcinosarcomas tended to be older and have unstaged tumors (P<0.0001). After adjusting for other prognostic factors, women with carcinosarcomas were 72% more likely to die from their tumors (HR=1.72; 95% CI, 1.52-1.96). Five-year survival for stage I carcinosarcomas was 65.2% (95% CI, 58.0-71.4%) vs. 80.6% (95% CI, 78.9-82.2%) for serous tumors. Similarly, five-year survival for stage IIIC patients was 18.2% (95% CI, 14.5-22.4%) for carcinosarcomas compared to 33.3% (95% 32.1-34.5%) for serous carcinomas. CONCLUSIONS: Ovarian carcinosarcomas are aggressive tumors with a natural history that is distinct from serous cancers. The survival for both early and late stage carcinosarcoma is inferior to serous tumors.
OBJECTIVE:Ovarian carcinosarcomas (OCS) are rare tumors composed of both malignant epithelial and mesenchymal elements. We compared the natural history and outcomes of OCS to serous carcinoma of the ovary. METHODS:Patients with OCS and serous carcinomas registered in the Surveillance, Epidemiology, and End Results (SEER) database between 1988 and 2007 were analyzed. Demographic and clinical characteristics were compared using chi square tests while survival was analyzed using Cox proportional hazards models and the Kaplan-Meier method. RESULTS: A total of 27,737 women, including 1763 (6.4%) with OCS and 25,974 (93.6%) with serous carcinomas, were identified. Patients with carcinosarcomas tended to be older and have unstaged tumors (P<0.0001). After adjusting for other prognostic factors, women with carcinosarcomas were 72% more likely to die from their tumors (HR=1.72; 95% CI, 1.52-1.96). Five-year survival for stage I carcinosarcomas was 65.2% (95% CI, 58.0-71.4%) vs. 80.6% (95% CI, 78.9-82.2%) for serous tumors. Similarly, five-year survival for stage IIIC patients was 18.2% (95% CI, 14.5-22.4%) for carcinosarcomas compared to 33.3% (95% 32.1-34.5%) for serous carcinomas. CONCLUSIONS:Ovarian carcinosarcomas are aggressive tumors with a natural history that is distinct from serous cancers. The survival for both early and late stage carcinosarcoma is inferior to serous tumors.
Authors: Lori Spoozak; Sharyn N Lewin; William M Burke; Israel Deutsch; Xuming Sun; Thomas J Herzog; Jason D Wright Journal: Am J Obstet Gynecol Date: 2011-07-22 Impact factor: 8.661
Authors: Jason D Wright; Ruvandhi Nathavithrana; Sharyn N Lewin; Xuming Sun; Israel Deutsch; William M Burke; Thomas J Herzog Journal: Obstet Gynecol Date: 2010-03 Impact factor: 7.661
Authors: Vera Loizzi; Gennaro Cormio; Anna Camporeale; Maddalena Falagario; Paola De Mitri; Doriana Scardigno; Giuseppe Putignano; Luigi E Selvaggi Journal: Oncology Date: 2011-06-14 Impact factor: 2.935
Authors: D-A Silasi; J L Illuzzi; M G Kelly; T J Rutherford; G Mor; M Azodi; P E Schwartz Journal: Int J Gynecol Cancer Date: 2007-04-19 Impact factor: 3.437
Authors: Perapong Inthasorn; Philip Beale; Christopher Dalrymple; Jonathan Carter Journal: Aust N Z J Obstet Gynaecol Date: 2003-02 Impact factor: 2.100
Authors: Jason D Wright; Monjri Shah; Leny Mathew; William M Burke; Jennifer Culhane; Noah Goldman; Peter B Schiff; Thomas J Herzog Journal: Cancer Date: 2009-09-15 Impact factor: 6.860
Authors: Yihua Liu; Zachary Weber; F Anthony San Lucas; Aditya Deshpande; Yasminka A Jakubek; Raed Sulaiman; Mary Fagerness; Natasha Flier; Joseph Sulaiman; Christel M Davis; Jerry Fowler; David Starks; Luis Rojas-Espaillat; Alexander J Lazar; Gareth E Davies; Erik A Ehli; Paul Scheet Journal: Gynecol Oncol Date: 2018-09-05 Impact factor: 5.482
Authors: Ibrahim Yalcin; Mehmet Mutlu Meydanli; Ahmet Taner Turan; Salih Taskin; Mustafa Erkan Sari; Tayfun Gungor; Ozgur Akbayir; Ali Ayhan Journal: Int J Clin Oncol Date: 2017-11-16 Impact factor: 3.402
Authors: Eman S A Saad; Jacqueline S Y Lam; Awf A Al-Khan; Mourad Tayebi; Michael J Day; Samantha J Richardson; Janine A Danks Journal: J Mammary Gland Biol Neoplasia Date: 2018-11-28 Impact factor: 2.673
Authors: Munveer S Bhangoo; Peter Boasberg; Pareen Mehta; Julia A Elvin; Siraj M Ali; Winnie Wu; Samuel J Klempner Journal: Oncologist Date: 2018-01-31
Authors: Siân Jones; Nicolas Stransky; Christine L McCord; Ethan Cerami; James Lagowski; Devon Kelly; Samuel V Angiuoli; Mark Sausen; Lisa Kann; Manish Shukla; Rosemary Makar; Laura D Wood; Luis A Diaz; Christoph Lengauer; Victor E Velculescu Journal: Nat Commun Date: 2014-09-19 Impact factor: 14.919